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We, the participants in NABC 4, have been presented with a tremendousamount of information—facts, perceptions, views, values and impacts on 
animal biotechnology. It has been a stimulating, mind-stretching and, yes at 
times, a stressful experience. In this meeting, we have not all really “heard” the 
same things even when we were in the same sessions listening to the same speak-
ers Certainly, we have developed individual impressions. We leave this meeting 
with many of us feeling a little uncomfortable—business representatives feeling 
as if they were at times considered the “bad guys.” Ditto for government repre-
sentatives and scientists, animal rights proponents and those with environmental 
interests. Let me suggest that NABC must be doing something right when partici-
pants do feel a bit uncomfortable, a little bit less sure after actually listening and 
hearing views different from their own; when representatives of different groups 
have had to articulate their positions to fellow participants who are unfamiliar 
with, and even disapprove of, their positions and actions. This forces communi-
cation, perhaps for the first time, with one another rather that at one another. If 
you are feeling just a bit less sure, if you have a bit more insight to the perspective 
of a different group, if you now know someone “from the opposition,” I declare 
NABC 4 a success.
Let me just review with you some of the opportunities and challenges we en-
countered as participants in this meeting. First, we need to examine some of the 
“specs” of the meeting that we are pull together here. As a benchmark, NABC 
Chair Ralph W. F. Hardy, in his charge to the meeting made several key points:
1. We are living in an era of biology with rapid change; 2. Yesterday’s science is 
perhaps but dreams; 3. Today’s science represents possibilities; 4. Tomorrow’s 
science will bring realities; 5. Dr. Hardy implored us to recognize that “risk” is 
product-based, not process-based; 6. Furthermore, he pointed out that we now 
have the knowledge base to allow a thorough look at risk; and 7. Finally, Dr. 
Hardy reminded us that the mission of NABC is that of “providing an open fo-
rum for exploring issues in agricultural biotechnology.” In conducting that open 
forum we come together to speak, to listen, to learn and to participate in mean-
ingful dialogue and evaluation of potential impacts of agricultural biotechnology. 
As I reflect on how well we responded to the charge, I note both some rewarding 
opportunities we have taken and others we left untouched as well as several chal-
lenges we, as individual participants, will take from this meeting.
OPPORTUNITIES
With this assemblage of diverse views and interests, I can only wish we had had 
more time to discuss more of the opportunities placed before us. Let me share my 
views about a few opportunities we missed.
The issue of patenting came up several times. As keynote speaker Dorothy 
Nelkin put it, “Patenting of animals has become a lightning rod.” I was disappoin-
ted that we did not take the opportunity to dissect the patenting issue and to exam-
ine the components. (I realize there is a special optional seminar that will place ad-
ditional emphasis on patenting, but not all participants will be at that activity.1 
There is a general perception that patents (in any field) inherently mean: 1. secrecy 
and 2. making money. I have learned, after having spoken to various university 
patent officers, that they support my own experiences which suggests the following: 
1. Most patents do not return many dollars in royalties; 2. The patent process makes 
information known to the public. One of the requirements for issuing a patent is 
that the details be disclosed; 3. The main reason why universities patent things is to 
encourage commercialization. Most products coming out of university research 
that may be patentable still require further research and development before be-
coming available to users. That means that some business organization must make 
additional investment of likelihood of the business getting a financial return on 
their own funds to bring the patented discovery to commercialization. There usu-
ally is significant risk about the investment; 4. It seems to me that licensing is the 
key issue that really should be addressed under the protection of intellectual prop-
erty by a university or other public sector entity. If a university owns the patent they 
can control the release for the best benefit to those who should be receiving the ben-
efit. In many cases, patents are licensed by the public sector to the private sector on 
a nonexclusive basis. However, sometimes it may be necessary to provide an exclu-
sive license so that a company can have sufficient incentive to cover the additional 
costs to complete the research and development and then test the marketability of 
the product or idea. There are times when an exclusive license may be the most appro-
priate way to proceed.
Another point about licensing is that the intellectual property can be licensed 
for less than the life of a patent. Thus, even if a university decided that it was in the 
best public interest to give an exclusive license, that would not have to be done for 
the life of the patent. It could be made available exclusively for a particular com-
pany’s use for, let us say, five years and after that then, the university may be in a 
position to license it to other companies. This sort of arrangement provides the ini-
tial company the lead time to complete the necessary development and have some 
headstart in the marketing area as an incentive for potential return on that upfront 
investment. If the university has not patented intellectual property in the first place, 
they would not have the option to control the route to commercialization.
I also noted that Dorothy Nelkin made an observation of a general nature: bio-
technology is not the cause of the decline of family farms and banning of patents 
would not likely reverse the trend in decline in the number of family farms. It was a
1 Editor’s note: NABC Occasional Paper #1, Ethics and Patenting of Transgenic Animals, 
is available from the NABC office.
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challenge that was not picked up by any other speaker, or to any significance, in any 
workshop.
NABC 4 provided an opportunity for fairly rigorous examination of animal 
biotechnology implications. I was surprised that there was not (at least in the ses-
sions I attended) more examination and analysis of issues (or the lack of) related 
specifically to each of the different tools and uses of biotechnology for animals:
1. Of course, artificial insemination has been common for 40 years and the subse-
quent advent of frozen semen represents really an early “biotechnology” that has 
had tremendous positive impact on the dairy industry and on the efficiency of dairy 
food production. At the present time, nearly three-fourths of the dairy cows in the 
U.S. are artificially inseminated using enhanced genetic material; 2. Control of re-
production involving ovulation, super-ovulation and estrous cycle regulation;
3. In vitro fertilization, perhaps with spermatozoan carrying X or Y chromosomes 
thus enabling control of sex of the offspring; 4. Embryo manipulations including di-
visions (cloning) and nuclear transfer; 5. Production of transgenic animals. Al-
though this area of animal biotechnology perhaps attracted the most attention, it is, 
in fact, currently only a very small component of all uses of biotechnology for ani-
mal agriculture; 6. Marker-assisted genetic selection through the use of techniques 
for gene mapping. This technology may turn out to be the most powerful tool 
for the intermediate time range; 7. Vaccines produced through biotechnologies;
8. Diagnostic tests; and 9. DNA probes. Each of these has a different set of advan-
tages and issues. It is unfortunate that we did not take this opportunity to look at 
each of the technologies individually, providing an analysis of the issues and poten-
tial outcomes of various alternatives.
OPPORTUNITIES TAKEN
Next, I would like to examine some of the opportunities taken, or overarching 
themes, which appear to me to at least link, if not tie together, the participants 
of NABC 4.
The first I would identify relates to animal well-being. Workshop participants 
were hard pressed to come up with a precise definition that was acceptable to all. 
While no attempt was made to achieve consensus overall, it seems to me that many 
participants in the workshop were saying: 1. Pain and suffering are no longer the 
only criteria to be considered; 2. Some feel “animal welfare” may be a minimum and 
that “well-being” means something above that in terms of production, reproduc-
tive performance, etc; 3. Animal well-being is important; and 4. Animal well-being 
is an important component of the biotechnology dialogue.
A second theme relates to meat and animal product safety. Again, I heard many 
people saying that healthy transgenic food animals are likely to be just as safe as a 
source of food as that from “traditional animals” from which they are derived. That 
goes along with the concept of looking at “product” and not “process.” I also heard 
many saying they wanted to know when their food was biotechnologically pro-
duced—a concern about labeling. A related theme is the clear need to continually 
examine, and perhaps broaden, our definitions and agendas for issues such as 
food safety, especially where food allergies are a concern.
Concluding Remarks
Finally, I often heard (and yet make no claim that there was an effort to achieve 
consensus) that biotechnology is not inherently, or universally, bad.
CHALLENGES
In addition, there were a few challenges to us as participants. These remind us that 
we all need to continue to listen, learn and share. One challenge to NABC was the 
need to broaden the representation of groups in the audience. It was pointed out 
that we especially need in the future to encourage greater participation of farmers, 
of food processors and, certainly, of consumers (as one individual put it, of “eaters”).
A second challenge: the regulatory process continues to be a concern and one 
for which it is very difficult to meet even an approximation of consensus among all 
of us and the groups we represent here at this meeting. Clearly we need more dia-
logue and meaningful interaction all through the year, not just for a few day once a year.
Perhaps the greatest challenge running through sessions and workshops even 
approaching consensus is two-fold: 1. the public will be more involved in decisions 
about biotechnology whether or not the traditional decision-makers invite them; 
and 2. there is a critical need for enhanced true communication. In discussing the 
public, we were reminded that we should not view public participation as an im-
pediment to change. This meeting reinforces some observations I have made from 
other vantage points, namely that “the public” is showing distrust, confusion and 
frustration not just about biotechnology and science, but also with government, 
legislators, etc.
I believe all of us must be seriously concerned that science may continue to lose 
credibility in the eyes of the public. Because science holds many keys to the future, a 
critical question is, “How are we going to develop and use science (e.g., biotechnol-
ogy) for the public good?” Scientists have a responsibility to provide information 
about science in understandable ways for all of society. “The public” must be in-
vited into the decision-making process as full, and informed, participants.
The second part of the major challenge from this NABC meeting is the need for 
enhanced communication. Participants clearly declared that by communication we 
do not mean “we need to educate the public.” Some of the sub-points in those dis-
cussions, and which I would challenge you to think about, are as follows:
—We must keep talking about issues and be open to compromise.
—Scientists have not done a good job of communicating what is going on.
There is a level of mistrust.
—Real communication is not just reaching someone with your message; it is 
interaction among equals who may not necessarily agree. As someone put it “don’t 
talk only with those who agree with you ... you’ll never learn anything.”
—Consumers are removed from agriculture and the production of food and fi-
ber. Since they do not see the various steps in the process they then have difficulty 
understanding this new animal biotechnology.
—The science community cannot just say that public concerns are unfounded. 
Public perception drives policy.
—And finally, special attention is needed to work with the media.
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I cannot leave this topic of communication without pointing out an old axiom, 
but one worth repeating—“we" must not just talk to our “own kind.” That is true 
whether our own kind means scientists, administrators, regulators, advocate and 
consumer group representatives, or any other segment of society. That is what 
NABC is all about—not talking only to our “own kind.”
I suggest that each of us go back from this meeting to our respective organiza-
tions with some action items. One that strikes me very clearly is about the develop-
ment of public policy. I am reminded that it is said about real estate that three things 
are important—location, location, location. If science is to have a role in the devel-
opment of public policy it seems to me that three things are important—communi-
cation, communication, communication.
I would hope that all of us, regardless of what group we consider ourselves to 
be affiliated with, would seriously consider these steps in communication: 1. Listen 
to a broad segment of society; 2. Listen carefully; 3. Frame a response; 4. Go back to 
our audiences with patience and persistence; 5. Listen to the audience once again; 
and 6. Keep up the cycle. It must become a part of our regular way of doing business.
Throughout this meeting we also heard the need for linkages—for coalitions. 
Each of us has a responsibility for our own organization in terms of seeking linkages 
and coordination. NABC provides a unique opportunity to enhance those efforts 
for appropriate development and use of agricultural biotechnology.
C O N C L U S I O N
In conclusion, let me confess that I have not been able to tie the box representing 
this meeting closed. In fact, I have decided that we do not have a box at all, but 
rather a vehicle. I urge each of you to consider the opportunities and challenges that 
we have shared during this meeting as fuel. It is now up to us to make that vehicle 
move forward. Let me leave you with the urgent plea that you communicate openly 
and fully with all stakeholders in agricultural biotechnology.
On a light note about a serious issue, perhaps it is not biotechnology per se that 
causes things to change. I believe that on his late night show Jay Leno said recently 
“the new McLean burger shows how times have changed. Now you find water and 
sea weed at McDonald’s and oil and grease in the ocean.”
Dr. W. Edwards Deming, (the American who finally gained fame for his suc-
cess in rebuilding Japan’s industry following World War II) repeatedly stresses the 
importance to “optimize the system so everybody wins. The best solution is for ev-
erybody to win.” NABC provides an open forum, a level playing field. Let us all 
work to keep the field level and the vehicle, fueled by this open forum, moving.
Finally a quote by Ralph Waldo Emerson, the American scholar, “This time 
like all times is a very good time, if we but know what to do with it.” I challenge us to 
communicate with each other and all the public. That is what we should do with 
“It” (our time).
Concluding Remarks
